University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

ExRNA Research May Refine Prostate Cancer Treatment

By UCSF Urology | February 3, 2014

ExRNA Research May Refine Prostate Cancer Treatment

Robert Blelloch, MD, PhD


Urology faculty member Robert Blelloch, MD, PhD, is leading an NIH-funded project examining the role extracellular RNA (exRNA) might play in prostate and other cancers. Within the cell, RNA helps to guide protein production, but scientists have learned in recent years that small segments of RNA are also found in blood and body fluids, where their role is not well understood.  
Blelloch’s lab at UCSF has been exploring exRNA for the past several years and found a correlation between the presence of exRNA and a commonly used prostate cancer risk asssessment score (the UCSF CAPRA). Working with Matthew Cooperberg, MD, MPH, and Peter Carroll, MD, MPH, Blelloch’s team subsequently examined exRNA in men who were eligible for active surveillance, but underwent prostatectomy. Some of the men were found to have more severe disease than predicted at initial diagnosis, and a preliminary study has found that in those patients, specific exRNA levels were increased prior to surgery.  This finding might lead to a new biomarker for the severity of prostate cancer or possibly even a new treatment approach, if exRNA is found to be fueling tumor growth.

Read more at UCSF Urology